Industry & Policy News

[The Institute of Cancer Research] Professor Nicholas Turner, Professor of Molecular Oncology at The Institute of Cancer Research, London, and Head of the Ralph Lauren Centre for Breast Cancer Research, has received the Translational Research Award by the European Society for Medical Oncology (ESMO).

[3D BioFibR (Financial Post)] 3D BioFibR, a leading innovator in biomaterials for tissue engineering, announced today it has raised over $3.52M in seed financing. The financing will be used to expand 3D BioFibR’s facilities to include a climate controlled biomanufacturing cleanroom and bring its premium collagen fiber products to market.

[Immix Biopharma, Inc.] Immix Biopharma, Inc. announced its 2nd positive IMX-110 interim update from the Company’s ongoing Phase IbIIa IMMINENT-01 study of IMX-110 in combination with BeiGene’s anti-PD-1 antibody tislelizumab.

[The Pennsylvania State University] Developing technology to quickly and efficiently bioprint human tissues at scale is the goal of a new project led by Penn State researchers.

[Qihan Biotech (Businesswire)] Hangzhou Qihan Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) approved its clinical trial application for the product QN-019a. It is the first IND approved in China for a gene-edited iPSC-derived cell therapy product.

[Sanofi] The US FDA has approved Sanofi and AstraZeneca’s Beyfortus™ for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants born during or entering their first RSV season.